We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
+12.27%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$365M
AUM Growth
+$21.1M
Cap. Flow
+$4.67M
Cap. Flow %
1.28%
Top 10 Hldgs %
92.74%
Holding
25
New
7
Increased
5
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ACRV icon
Acrivon Therapeutics
ACRV
+$21M
2
SNOW icon
Snowflake
SNOW
+$139K
3
CPNG icon
Coupang
CPNG
+$123K
4
CRWD icon
CrowdStrike
CRWD
+$118K
5
DASH icon
DoorDash
DASH
+$107K

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13M
2
RGEN icon
Repligen
RGEN
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 49.48%
2 Technology 22.98%
3 Financials 10.21%
4 Consumer Discretionary 8.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
1
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$85.8M 23.49%
2,748,970
-400,000
-13% -$13M
PATH icon
2
UiPath
PATH
$8.3B
$48.5M 13.29%
3,816,569
+4,790
+0.1% +$59.2K
NU icon
3
Nu Holdings
NU
$73.6B
$37.3M 10.21%
9,156,347
+19,512
+0.2% +$84.8K
SNOW icon
4
Snowflake
SNOW
$114B
$30.9M 8.47%
215,535
+914
+0.4% +$139K
DASH icon
5
DoorDash
DASH
$94B
$29.5M 8.07%
603,512
+2,058
+0.3% +$107K
ACRV icon
6
Acrivon Therapeutics
ACRV
$83.6M
$19M 5.21%
+1,652,605
New +$21M
ABOS icon
7
Acumen Pharmaceuticals
ABOS
$193M
$18.5M 5.05%
3,417,075
– –
OLK
8
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$17.9M 4.9%
705,514
– –
TXG icon
9
10x Genomics
TXG
$7.31B
$17.6M 4.81%
481,770
– –
KRTX
10
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$11.6M 3.17%
58,895
– –
IOT icon
11
Samsara
IOT
$23.2B
$4.13M 1.13%
332,520
+6,520
+2% +$74.2K
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.04B
$3.81M 1.04%
260,000
– –
MASS icon
13
908 Devices
MASS
$414M
$2.49M 0.68%
326,427
– –
TSHA icon
14
Taysha Gene Therapies
TSHA
$1.94B
$1.64M 0.45%
724,873
– –
CADL icon
15
Candel Therapeutics
CADL
$897M
$1.45M 0.4%
811,737
– –
SPRB
16
Spruce Biosciences
SPRB
$151M
$866K 0.24%
10,493
– –
ABSI icon
17
Absci
ABSI
$1.58B
$121K 0.03%
57,804
– –
CPNG icon
18
Coupang
CPNG
$29B
$103K 0.03%
+6,971
New +$123K
DDOG icon
19
Datadog
DDOG
$91.7B
$100K 0.03%
+1,366
New +$107K
CRWD icon
20
CrowdStrike
CRWD
$221B
$91K 0.02%
+3,456
New +$118K
TOST icon
21
Toast
TOST
$20.1B
$81K 0.02%
+4,494
New +$84.5K
CFLT
22
DELISTED
Confluent
CFLT
$30K 0.01%
+1,354
New +$31.4K
GTLB icon
23
GitLab
GTLB
$7.2B
$30K 0.01%
+658
New +$29.7K
RGEN icon
24
Repligen
RGEN
$9.42B
– –
-22,544
Closed -$4.22M

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q4 2022 Portfolio in Review

As of Q4 2022, Sands Capital Ventures held 25 positions worth $365M, up 6.1% from $344M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Sands Capital Ventures's Q4 2022 filing shows 7 new, 5 increased, 1 reduced and 1 closed positions. Its largest new stake was Acrivon Therapeutics: 1,652,605 shares worth $19M. The largest sale was DICE Therapeutics, Inc. Common Stock, an estimated $13M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 44% a quarter earlier, followed by Technology and Financials.

  • Sands Capital Ventures's largest Q4 2022 buy was Acrivon Therapeutics: 1,652,605 shares worth $19M.
  • Sands Capital Ventures added most to Snowflake in Q4 2022, an estimated $139K increase.
  • Sands Capital Ventures's biggest Q4 2022 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $13M.
  • Sands Capital Ventures fully exited Repligen in Q4 2022, selling an estimated $4.22M.
  • Sands Capital Ventures's ten largest holdings make up 93% of its $365M portfolio in Q4 2022.
  • Sands Capital Ventures opened 7 new positions and closed 1 in Q4 2022.
  • Sands Capital Ventures's portfolio value rose 6.1% quarter-over-quarter to $365M.

Based on Sands Capital Ventures's 13F filing for Q4 2022, filed 13 Feb 2023.